vs
FIRST HAWAIIAN, INC.（FHB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
FIRST HAWAIIAN, INC.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$220.3M vs $207.3M），FIRST HAWAIIAN, INC.净利率更高（30.8% vs -62.0%，领先92.8%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 3.8%）
第一夏威夷公司是总部位于夏威夷檀香山的银行控股企业，核心子公司第一夏威夷银行成立于1858年，是夏威夷历史最悠久、规模最大的金融机构，总部设在檀香山第一夏威夷中心。该行在夏威夷设有57家分支机构，关岛有3家，塞班岛有1家，为个人及商业客户提供存款、贷款、财富管理、保险、私人银行等多元金融服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FHB vs RARE — 直观对比
营收规模更大
FHB
是对方的1.1倍
$207.3M
净利率更高
FHB
高出92.8%
-62.0%
两年增速更快
RARE
近两年复合增速
3.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $220.3M | $207.3M |
| 净利润 | $67.8M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 30.8% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | 14.4% | 3.5% |
| 每股收益（稀释后） | $0.55 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FHBRARE
| Q1 26 | $220.3M | — | ||
| Q4 25 | $225.9M | $207.3M | ||
| Q3 25 | $226.4M | $159.9M | ||
| Q2 25 | $217.5M | $166.5M | ||
| Q1 25 | $211.0M | $139.3M | ||
| Q4 24 | $188.1M | $164.6M | ||
| Q3 24 | $210.0M | $139.5M | ||
| Q2 24 | $204.6M | $147.0M |
净利润FHBRARE
| Q1 26 | $67.8M | — | ||
| Q4 25 | $69.9M | $-128.6M | ||
| Q3 25 | $73.8M | $-180.4M | ||
| Q2 25 | $73.2M | $-115.0M | ||
| Q1 25 | $59.2M | $-151.1M | ||
| Q4 24 | $52.5M | $-133.2M | ||
| Q3 24 | $61.5M | $-133.5M | ||
| Q2 24 | $61.9M | $-131.6M |
营业利润率FHBRARE
| Q1 26 | — | — | ||
| Q4 25 | 41.2% | -54.7% | ||
| Q3 25 | 42.5% | -106.9% | ||
| Q2 25 | 40.5% | -64.8% | ||
| Q1 25 | 36.5% | -102.6% | ||
| Q4 24 | 34.4% | -74.3% | ||
| Q3 24 | 36.4% | -94.6% | ||
| Q2 24 | 39.5% | -79.1% |
净利率FHBRARE
| Q1 26 | 30.8% | — | ||
| Q4 25 | 31.0% | -62.0% | ||
| Q3 25 | 32.6% | -112.8% | ||
| Q2 25 | 33.7% | -69.0% | ||
| Q1 25 | 28.1% | -108.5% | ||
| Q4 24 | 27.9% | -80.9% | ||
| Q3 24 | 29.3% | -95.7% | ||
| Q2 24 | 30.3% | -89.5% |
每股收益（稀释后）FHBRARE
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.56 | $-1.28 | ||
| Q3 25 | $0.59 | $-1.81 | ||
| Q2 25 | $0.58 | $-1.17 | ||
| Q1 25 | $0.47 | $-1.57 | ||
| Q4 24 | $0.41 | $-1.34 | ||
| Q3 24 | $0.48 | $-1.40 | ||
| Q2 24 | $0.48 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $2.8B | $-80.0M |
| 总资产 | $24.3B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资FHBRARE
| Q1 26 | — | — | ||
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M |
总债务FHBRARE
| Q1 26 | $0 | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益FHBRARE
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $-80.0M | ||
| Q3 25 | $2.7B | $9.2M | ||
| Q2 25 | $2.7B | $151.3M | ||
| Q1 25 | $2.6B | $144.2M | ||
| Q4 24 | $2.6B | $255.0M | ||
| Q3 24 | $2.6B | $346.8M | ||
| Q2 24 | $2.6B | $432.4M |
总资产FHBRARE
| Q1 26 | $24.3B | — | ||
| Q4 25 | $24.0B | $1.5B | ||
| Q3 25 | $24.1B | $1.2B | ||
| Q2 25 | $23.8B | $1.3B | ||
| Q1 25 | $23.7B | $1.3B | ||
| Q4 24 | $23.8B | $1.5B | ||
| Q3 24 | $23.8B | $1.5B | ||
| Q2 24 | $24.0B | $1.6B |
负债/权益比FHBRARE
| Q1 26 | 0.00× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流FHBRARE
| Q1 26 | — | — | ||
| Q4 25 | $335.1M | $-99.8M | ||
| Q3 25 | $57.1M | $-91.4M | ||
| Q2 25 | $136.4M | $-108.3M | ||
| Q1 25 | $36.7M | $-166.5M | ||
| Q4 24 | $317.5M | $-79.3M | ||
| Q3 24 | $58.9M | $-67.0M | ||
| Q2 24 | $78.2M | $-77.0M |
自由现金流FHBRARE
| Q1 26 | — | — | ||
| Q4 25 | $303.3M | $-100.8M | ||
| Q3 25 | $49.5M | $-92.7M | ||
| Q2 25 | $125.2M | $-110.7M | ||
| Q1 25 | $28.6M | $-167.8M | ||
| Q4 24 | $288.7M | $-79.5M | ||
| Q3 24 | $52.3M | $-68.6M | ||
| Q2 24 | $72.2M | $-79.0M |
自由现金流率FHBRARE
| Q1 26 | — | — | ||
| Q4 25 | 134.3% | -48.6% | ||
| Q3 25 | 21.9% | -58.0% | ||
| Q2 25 | 57.5% | -66.5% | ||
| Q1 25 | 13.6% | -120.5% | ||
| Q4 24 | 153.5% | -48.3% | ||
| Q3 24 | 24.9% | -49.2% | ||
| Q2 24 | 35.3% | -53.7% |
资本支出强度FHBRARE
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 0.5% | ||
| Q3 25 | 3.3% | 0.8% | ||
| Q2 25 | 5.2% | 1.5% | ||
| Q1 25 | 3.8% | 1.0% | ||
| Q4 24 | 15.3% | 0.1% | ||
| Q3 24 | 3.1% | 1.2% | ||
| Q2 24 | 2.9% | 1.4% |
现金转化率FHBRARE
| Q1 26 | — | — | ||
| Q4 25 | 4.79× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 1.86× | — | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | 6.05× | — | ||
| Q3 24 | 0.96× | — | ||
| Q2 24 | 1.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FHB
| Net Interest Income | $167.5M | 76% |
| Noninterest Income | $52.8M | 24% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
